PELL Bio-Med Technology Co (TPE:6949) ROCE % : -27.99% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is PELL Bio-Med Technology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PELL Bio-Med Technology Co's annualized ROCE % for the quarter that ended in Dec. 2024 was -27.99%.

PELL Bio-Med Technology Co ROCE % Historical Data

The historical data trend for PELL Bio-Med Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PELL Bio-Med Technology Co ROCE % Chart

PELL Bio-Med Technology Co Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROCE %

-53.60

-34.40

-34.43

-28.55

PELL Bio-Med Technology Co Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial						-36.78	-23.58	-25.75	-26.17	-27.99

PELL Bio-Med Technology Co ROCE % Calculation

PELL Bio-Med Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-392.855	/	( ( (1418.156 - 89.298)	+	(1744.832 - 321.35) )	/ 2 )
	=	-392.855	/	( (1328.858	+	1423.482)	/ 2 )
	=	-392.855	/	1376.17
	=	-28.55 %

PELL Bio-Med Technology Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-412.264	/	( ( (1624.121 - 101.946)	+	(1744.832 - 321.35) )	/ 2 )
	=	-412.264	/	( ( 1522.175	+	1423.482 )	/ 2 )
	=	-412.264	/	1472.8285
	=	-27.99 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

PELL Bio-Med Technology Co (TPE:6949) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PELL Bio-Med Technology Co ROCE % Related Terms

Thank you for viewing the detailed overview of PELL Bio-Med Technology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PELL Bio-Med Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PELL Bio-Med Technology Co Ltd (TPE:6949) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, TWN

Website

https://www.pellbmt.com

PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell).

PELL Bio-Med Technology Co Headlines

No Headlines